Neurotrophic Keratitis Threatens Vision Through Silent Corneal Nerve Damage
A rare but vision-threatening corneal disease caused by impaired nerve function progresses silently — here's what clinicians need to know.
Summary
Neurotrophic keratitis is a degenerative corneal disease stemming from trigeminal nerve damage, affecting roughly 5 per 10,000 individuals. Because corneal sensation is reduced or absent, patients rarely feel pain, making early diagnosis difficult. The disease progresses through three Mackie stages — from epithelial irregularities to persistent epithelial defects to corneal ulceration and potential perforation. Causes include herpetic infections, diabetes, refractive surgery, and autoimmune conditions. Treatment ranges from preservative-free artificial tears and autologous serum drops to recombinant nerve growth factor (cenegermin), amniotic membrane transplantation, and the emerging technique of corneal neurotization. Future therapies including stem cell treatment, gene-based neurotrophic delivery, and bioengineered corneas offer growing promise for restoring corneal health and vision.
Detailed Summary
Neurotrophic keratitis (NK) is a rare but serious degenerative disease of the cornea that results from impaired sensory innervation, primarily involving the trigeminal nerve's afferent fibers. First described experimentally in 1824, it affects approximately 5 per 10,000 individuals and is frequently underdiagnosed because the hallmark symptom — pain — is absent due to diminished or absent corneal sensation.
The corneal nerves are essential for maintaining ocular surface homeostasis. They regulate epithelial cell proliferation, stabilize the tear film, and modulate immune responses through trophic factors such as substance P, nerve growth factor (NGF), and IGF-1. When these nerves are disrupted — by herpes simplex or varicella-zoster infections, diabetes mellitus, surgical trauma, chemical burns, chronic topical drug use, or autoimmune diseases like Sjögren syndrome — the cornea loses its protective mechanisms and becomes vulnerable to ulceration, infection, and perforation.
Disease progression follows the Mackie classification: Stage 1 presents with punctate keratopathy and epithelial irregularities; Stage 2 involves persistent epithelial defects (PEDs) with stromal involvement; Stage 3 encompasses frank ulceration, stromal melting, and possible perforation. Progression is insidious, with most patients presenting only with blurred vision or mild redness.
Diagnosis relies on corneal sensation testing (Cochet-Bonnet esthesiometer), slit-lamp examination, fluorescein staining, and advanced imaging including in vivo confocal microscopy to assess subbasal nerve plexus density. Treatment is staged and multimodal: lubricants and bandage lenses for early disease; recombinant NGF (cenegermin/Oxervate), platelet-rich plasma, and autologous serum for moderate cases; and tarsorrhaphy, amniotic membrane transplantation, corneal neurotization, or keratoplasty for severe cases.
Emerging regenerative therapies — mesenchymal stem cells, gene-based neurotrophic factor delivery, and bioengineered corneas — represent the frontier of NK management. An interprofessional approach involving ophthalmologists, neurologists, and cornea specialists is essential for optimizing outcomes.
Key Findings
- NK affects ~5 per 10,000 people and is often missed due to absent corneal pain despite active tissue damage.
- Trigeminal nerve damage from HSV, diabetes, surgery, or autoimmune disease disrupts trophic corneal nerve factors.
- The Mackie 3-stage classification guides treatment, from lubricants to keratoplasty based on severity.
- Recombinant NGF (cenegermin/Oxervate) stimulates nerve regeneration and improves epithelial healing in advanced stages.
- Corneal neurotization — transplanting sensory nerves — offers a promising surgical route to restoring corneal sensation.
Methodology
This is a comprehensive narrative review published as a StatPearls reference chapter, updated through March 2025. It synthesizes published clinical and experimental literature on NK pathophysiology, diagnosis, staging, and treatment. No original clinical trial data or meta-analysis was conducted by the authors.
Study Limitations
As a review/reference chapter rather than an original research study, this article does not provide new clinical data or statistical outcomes. Evidence quality for emerging therapies like corneal neurotization and stem cell treatment varies and is largely based on case series. The rarity of NK limits large-scale randomized controlled trial evidence, making many treatment recommendations expert-consensus based.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.